<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">2185302</PMID>
      <DateCompleted>
        <Year>1990</Year>
        <Month>06</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0268-1315</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1990</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>International clinical psychopharmacology</Title>
          <ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxazepam: update 1989.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>1-15</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Oxazepam is an anxiolytic with established clinical efficacy. Compared to other benzodiazepines it may offer advantages in some patient populations, such as the elderly. Oxazepam has not been associated with more or different risks than other benzodiazepines, and there is no evidence that physiological dependence occurs more frequently with oxazepam than other benzodiazepines. Available evidence suggests that oxazepam may be associated with a lower risk of seizure-induction than lorazepam and alprazolam, and that compared to diazepam, oxazepam may have lower abuse potential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayd</LastName>
            <ForeName>F J</ForeName>
            <Initials>FJ</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>West Virginia University Medical Center, Charleston.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Int Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8609061</NlmUniqueID>
        <ISSNLinking>0268-1315</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>6GOW6DWN2A</RegistryNumber>
          <NameOfSubstance UI="D010076">Oxazepam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010076" MajorTopicYN="Y">Oxazepam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>54</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1990</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2001</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1990</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2185302</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">2185302</PMID>
      <DateCompleted>
        <Year>1990</Year>
        <Month>06</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0268-1315</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>5</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>1990</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>International clinical psychopharmacology</Title>
          <ISOAbbreviation>Int Clin Psychopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oxazepam: update 1989.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>1-15</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Oxazepam is an anxiolytic with established clinical efficacy. Compared to other benzodiazepines it may offer advantages in some patient populations, such as the elderly. Oxazepam has not been associated with more or different risks than other benzodiazepines, and there is no evidence that physiological dependence occurs more frequently with oxazepam than other benzodiazepines. Available evidence suggests that oxazepam may be associated with a lower risk of seizure-induction than lorazepam and alprazolam, and that compared to diazepam, oxazepam may have lower abuse potential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayd</LastName>
            <ForeName>F J</ForeName>
            <Initials>FJ</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>West Virginia University Medical Center, Charleston.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Int Clin Psychopharmacol</MedlineTA>
        <NlmUniqueID>8609061</NlmUniqueID>
        <ISSNLinking>0268-1315</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>6GOW6DWN2A</RegistryNumber>
          <NameOfSubstance UI="D010076">Oxazepam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010076" MajorTopicYN="Y">Oxazepam</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>54</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1990</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2001</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1990</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2185302</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
